Back to Screener

Evaxion A/S American Depositary Share (EVAX)

Price$4.49

Favorite Metrics

Price vs S&P 500 (26W)-33.32%
Price vs S&P 500 (4W)4.32%
Market Capitalization$37.11M

All Metrics

Book Value / Share (Quarterly)$0.02
P/TBV (Annual)4.96x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.04
Price vs S&P 500 (YTD)-10.85%
Net Profit Margin (TTM)-50.24%
EPS (TTM)$-0.04
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.04
EPS (Annual)$-0.02
ROI (Annual)-31.40%
Cash / Share (Quarterly)$0.05
Revenue Growth QoQ (YoY)148.33%
ROA (Last FY)-27.13%
Revenue Growth TTM (YoY)125.15%
EBITD / Share (TTM)$-0.02
ROE (5Y Avg)-146.57%
Operating Margin (TTM)-69.77%
Cash Flow / Share (Annual)$-0.18
P/B Ratio2.18x
P/B Ratio (Quarterly)1.77x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.73x
Net Interest Coverage (TTM)-3.42x
ROA (TTM)-48.75%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)5.85x
Quick Ratio (Quarterly)5.66x
3-Month Avg Trading Volume0.06M
52-Week Price Return239.69%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.34
P/S Ratio (Annual)4.93x
Asset Turnover (Annual)0.27x
52-Week High$12.15
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)-43.07%
26-Week Price Return-24.58%
Quick Ratio (Annual)5.70x
13-Week Price Return-12.06%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)5.85x
Enterprise Value$21.384
Asset Turnover (TTM)0.19x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-114.44%
Cash / Share (Annual)$0.08
3-Month Return Std Dev86.47%
Net Income / Employee (TTM)$-0
ROE (Last FY)-45.23%
Net Interest Coverage (Annual)-1.08x
EPS Basic Excl Extra (Annual)$-0.02
Total Debt / Equity (Quarterly)0.44x
EPS Incl Extra (TTM)$-0.04
ROI (TTM)-71.05%
P/S Ratio (TTM)4.85x
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.34
Price vs S&P 500 (52W)204.60%
Year-to-Date Return-6.71%
5-Day Price Return7.49%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-89.94%
Net Profit Margin (Annual)-102.38%
Month-to-Date Return19.62%
EBITD / Share (Annual)$-0.02
Operating Margin (Annual)-88.55%
LT Debt / Equity (Annual)0.31x
ROI (5Y Avg)-111.21%
LT Debt / Equity (Quarterly)0.31x
EPS Basic Excl Extra (TTM)$-0.04
P/TBV (Quarterly)4.96x
P/B Ratio (Annual)1.77x
Pretax Margin (TTM)-59.78%
Book Value / Share (Annual)$0.34
Price vs S&P 500 (13W)-14.92%
Beta0.25x
Revenue / Share (TTM)$0.02
ROE (TTM)-111.18%
52-Week Low$1.25

Industry Peers — Biological Products(88)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
EVAXEvaxion A/S American Depositary Share
4.85x125.15%$4.49
AMGNAmgen Inc
5.20x9.95%73.30%2.93%$350.16
GILDGilead Sciences Inc
5.71x2.40%78.83%133.64%$135.87
ARGXargenx SE American Depositary Shares
12.59x89.56%150.91%$834.45
BNTXBioNTech SE American Depositary Share
9.06x-11.81%84.21%$105.19
BIIBBiogen Inc. Common Stock
2.72x2.22%75.69%-18.77%$183.34
MRNAModerna, Inc. Common Stock
10.91x-39.93%70.32%$54.59
NBIXNeurocrine Biosciences Inc
4.64x21.45%98.18%2.31%$131.59
EXELExelixis Inc
4.89x6.85%96.39%31.10%$43.61
TECHBio-Techne Corp.
7.72x1.64%66.60%-20.58%$60.58
IBRXImmunityBio, Inc. Common Stock
74.42x668.31%99.34%$8.20

About

Evaxion is a clinical-stage TechBio company developing personalized cancer vaccines and vaccines for infectious diseases using its proprietary AI-Immunology platform. The AI-driven platform decodes the immune system to identify novel vaccine candidates for cancer and bacterial/viral diseases with high unmet medical needs. With candidates advancing through clinical development, Evaxion aims to transform patient outcomes through targeted therapeutic innovations.